Chapin Davis Inc. Has $6.57 Million Position in Johnson & Johnson $JNJ

Chapin Davis Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.2% in the second quarter, HoldingsChannel reports. The institutional investor owned 25,860 shares of the company’s stock after selling 2,924 shares during the period. Johnson & Johnson accounts for about 1.2% of Chapin Davis Inc.’s holdings, making the stock its 24th biggest position. Chapin Davis Inc.’s holdings in Johnson & Johnson were worth $6,568,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Auto Owners Insurance Co grew its position in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $6,924,523,000. Capital World Investors bought a new position in Johnson & Johnson in the 4th quarter worth approximately $2,005,942,000. Diamant Asset Management Inc. increased its position in Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after acquiring an additional 4,454,778 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA clearance expands J&J’s growth opportunities. The FDA authorized Johnson & Johnson’s OTTAVA robotic surgery system, marking the company’s entry into surgical robotics. Investors may view the platform as a long-term medical-device growth driver and a way to diversify beyond pharmaceuticals. Johnson & Johnson Gets FDA Nod for OTTAVA
• Positive Sentiment: Analysts continue to support JNJ’s outlook. Wells Fargo reportedly expects the stock to rise, while other market commentary identifies Johnson & Johnson as an attractive blue-chip and dependable dividend stock. The company’s latest quarter also showed earnings and revenue exceeding estimates, with full-year 2026 earnings guidance maintained at $11.60-$11.75 per share. Wells Fargo Analyst Expects Johnson & Johnson Stock to Rise
• Positive Sentiment: Dividend appeal is supporting defensive demand. JNJ is being highlighted alongside other Dividend Aristocrats for dependable income. Its large scale, 21.48% net margin, 32.42% return on equity and low-beta profile may appeal to investors seeking stability while broader equity valuations remain elevated. Strong Buy Dividend Aristocrat Stocks
• Neutral Sentiment: Leadership transition adds a near-term watchpoint. Innovative Medicine chairman Jennifer Taubert will retire after more than two decades at J&J, with Tom Cavanaugh set to succeed her in September. Taubert helped build the segment into a business generating more than $60 billion in annual revenue, making execution under the new leader important for investors. Johnson & Johnson Leadership Change

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on JNJ shares. Sanford C. Bernstein upped their target price on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Guggenheim reiterated a “buy” rating and issued a $270.00 target price on shares of Johnson & Johnson in a research note on Friday, July 17th. HSBC set a $290.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, July 6th. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Bank of America lifted their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $267.48.

Johnson & Johnson Price Performance

NYSE JNJ opened at $257.77 on Thursday. Johnson & Johnson has a 52-week low of $169.68 and a 52-week high of $274.90. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The business has a 50 day simple moving average of $247.27 and a 200 day simple moving average of $239.32. The stock has a market cap of $621.21 billion, a price-to-earnings ratio of 29.87, a PEG ratio of 2.42 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same period in the previous year, the firm posted $2.77 EPS. The firm’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts anticipate that Johnson & Johnson will post 11.69 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.